Heather Y F Yong, Rajiv W Jain, Maria Goiko, Nicholas J Batty, Serena Phillips, Mankarman Ghuman, Marcus Werner Koch, Carlos Camara-Lemarroy
{"title":"血管生成和缺氧生物标志物在进展性多发性硬化中失调。","authors":"Heather Y F Yong, Rajiv W Jain, Maria Goiko, Nicholas J Batty, Serena Phillips, Mankarman Ghuman, Marcus Werner Koch, Carlos Camara-Lemarroy","doi":"10.1212/NXI.0000000000200477","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Multiple sclerosis (MS) is a neuroinflammatory and neurodegenerative CNS disorder characterized by a state of \"virtual hypoxia.\" Angiogenesis, one of the main homeostatic responses to hypoxia, has been implicated in the pathophysiology of MS. The study objective was to determine whether angiogenic and hypoxia-related molecules are dysregulated in the serum and CNS of patients with progressive multiple sclerosis (PMS).</p><p><strong>Methods: </strong>Baseline serum samples were obtained from a phase II trial of Ibudilast in PMS (n = 203 analyzed) and matched to healthy controls (n = 53). Participants on previous therapeutics (interferons or glatiramer acetate) were excluded from analysis (n = 131). Angiogenic factors were measured using a commercially available bead-based multiplex assay, and hypoxia biomarkers were measured using a custom bead-based multiplex assay. To interrogate the expression of selected hypoxia and angiogenic markers in the CNS, we analyzed publicly available transcriptomic databases and in-house generated data from normal appearing white matter of 2 SPMS donors and 2 nonneurologic disease controls.</p><p><strong>Results: </strong>Circulating markers of hypoxia (such as hypoxia inducible factor-1-a, heme oxygenase-1, and heat shock protein-90) were increased in serum. Conversely, markers of angiogenesis (such as vascular endothelial growth factor-A [VEGF-A], heparin-binding epidermal growth factor, and hepatocyte growth factor) were reduced suggesting a blunting of the angiogenic response. Several of these changes were confirmed in the PMS CNS transcriptome. Lower levels of VEGF-A were associated with disability worsening on the timed-25 foot-walk test at 24 (<i>p</i> = 0.02) and 48 (<i>p</i> = 0.02) weeks and predicted disability worsening (hazard ratio 0.31, 95% CI 0.14-0.69, <i>p</i> = 0.034). Conversely, higher leptin levels trended to predict cognitive worsening on the symbol digit modalities test.</p><p><strong>Discussion: </strong>Hypoxia-angiogenesis signals are dysregulated in PMS. Increased hypoxia and an insufficient angiogenic adaptive response may play a role in PMS pathophysiology and be a relevant pathway, both in understanding disease mechanisms and as a possible therapeutic target.</p>","PeriodicalId":19472,"journal":{"name":"Neurology® Neuroimmunology & Neuroinflammation","volume":"12 6","pages":"e200477"},"PeriodicalIF":7.5000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448328/pdf/","citationCount":"0","resultStr":"{\"title\":\"Angiogenesis and Hypoxia Biomarkers Are Dysregulated in Progressive Multiple Sclerosis.\",\"authors\":\"Heather Y F Yong, Rajiv W Jain, Maria Goiko, Nicholas J Batty, Serena Phillips, Mankarman Ghuman, Marcus Werner Koch, Carlos Camara-Lemarroy\",\"doi\":\"10.1212/NXI.0000000000200477\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>Multiple sclerosis (MS) is a neuroinflammatory and neurodegenerative CNS disorder characterized by a state of \\\"virtual hypoxia.\\\" Angiogenesis, one of the main homeostatic responses to hypoxia, has been implicated in the pathophysiology of MS. The study objective was to determine whether angiogenic and hypoxia-related molecules are dysregulated in the serum and CNS of patients with progressive multiple sclerosis (PMS).</p><p><strong>Methods: </strong>Baseline serum samples were obtained from a phase II trial of Ibudilast in PMS (n = 203 analyzed) and matched to healthy controls (n = 53). Participants on previous therapeutics (interferons or glatiramer acetate) were excluded from analysis (n = 131). Angiogenic factors were measured using a commercially available bead-based multiplex assay, and hypoxia biomarkers were measured using a custom bead-based multiplex assay. To interrogate the expression of selected hypoxia and angiogenic markers in the CNS, we analyzed publicly available transcriptomic databases and in-house generated data from normal appearing white matter of 2 SPMS donors and 2 nonneurologic disease controls.</p><p><strong>Results: </strong>Circulating markers of hypoxia (such as hypoxia inducible factor-1-a, heme oxygenase-1, and heat shock protein-90) were increased in serum. Conversely, markers of angiogenesis (such as vascular endothelial growth factor-A [VEGF-A], heparin-binding epidermal growth factor, and hepatocyte growth factor) were reduced suggesting a blunting of the angiogenic response. Several of these changes were confirmed in the PMS CNS transcriptome. Lower levels of VEGF-A were associated with disability worsening on the timed-25 foot-walk test at 24 (<i>p</i> = 0.02) and 48 (<i>p</i> = 0.02) weeks and predicted disability worsening (hazard ratio 0.31, 95% CI 0.14-0.69, <i>p</i> = 0.034). Conversely, higher leptin levels trended to predict cognitive worsening on the symbol digit modalities test.</p><p><strong>Discussion: </strong>Hypoxia-angiogenesis signals are dysregulated in PMS. Increased hypoxia and an insufficient angiogenic adaptive response may play a role in PMS pathophysiology and be a relevant pathway, both in understanding disease mechanisms and as a possible therapeutic target.</p>\",\"PeriodicalId\":19472,\"journal\":{\"name\":\"Neurology® Neuroimmunology & Neuroinflammation\",\"volume\":\"12 6\",\"pages\":\"e200477\"},\"PeriodicalIF\":7.5000,\"publicationDate\":\"2025-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448328/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurology® Neuroimmunology & Neuroinflammation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1212/NXI.0000000000200477\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology® Neuroimmunology & Neuroinflammation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1212/NXI.0000000000200477","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景和目的:多发性硬化症(MS)是一种神经炎症和神经退行性中枢神经系统疾病,以“虚拟缺氧”状态为特征。血管生成是对缺氧的主要稳态反应之一,与ms的病理生理有关。研究目的是确定进行性多发性硬化症(PMS)患者血清和中枢神经系统中血管生成和缺氧相关分子是否失调。方法:从伊布司特治疗经前症候群的II期试验中获得基线血清样本(n = 203例分析),并与健康对照(n = 53)相匹配。既往治疗(干扰素或醋酸格拉替默)的参与者被排除在分析之外(n = 131)。血管生成因子使用市售的基于头部的多重测定法进行测量,缺氧生物标志物使用定制的基于头部的多重测定法进行测量。为了研究中枢神经系统中选定的缺氧和血管生成标志物的表达,我们分析了公开可用的转录组数据库和内部生成的数据,这些数据来自2名SPMS供者和2名非神经系统疾病对照者的正常白质。结果:血清缺氧诱导因子-1-a、血红素加氧酶-1、热休克蛋白-90等循环指标升高。相反,血管生成标志物(如血管内皮生长因子- a [VEGF-A]、肝素结合表皮生长因子和肝细胞生长因子)减少,表明血管生成反应减弱。其中一些变化在PMS CNS转录组中得到证实。在24周(p = 0.02)和48周(p = 0.02)时,较低水平的VEGF-A与残疾恶化相关,并预测残疾恶化(风险比0.31,95% CI 0.14-0.69, p = 0.034)。相反,高瘦素水平倾向于预测符号数字模式测试中的认知恶化。讨论:经前症候群缺氧血管生成信号失调。缺氧增加和血管生成适应性反应不足可能在经前症候群的病理生理中发挥作用,并可能成为理解疾病机制和可能的治疗靶点的相关途径。
Angiogenesis and Hypoxia Biomarkers Are Dysregulated in Progressive Multiple Sclerosis.
Background and objectives: Multiple sclerosis (MS) is a neuroinflammatory and neurodegenerative CNS disorder characterized by a state of "virtual hypoxia." Angiogenesis, one of the main homeostatic responses to hypoxia, has been implicated in the pathophysiology of MS. The study objective was to determine whether angiogenic and hypoxia-related molecules are dysregulated in the serum and CNS of patients with progressive multiple sclerosis (PMS).
Methods: Baseline serum samples were obtained from a phase II trial of Ibudilast in PMS (n = 203 analyzed) and matched to healthy controls (n = 53). Participants on previous therapeutics (interferons or glatiramer acetate) were excluded from analysis (n = 131). Angiogenic factors were measured using a commercially available bead-based multiplex assay, and hypoxia biomarkers were measured using a custom bead-based multiplex assay. To interrogate the expression of selected hypoxia and angiogenic markers in the CNS, we analyzed publicly available transcriptomic databases and in-house generated data from normal appearing white matter of 2 SPMS donors and 2 nonneurologic disease controls.
Results: Circulating markers of hypoxia (such as hypoxia inducible factor-1-a, heme oxygenase-1, and heat shock protein-90) were increased in serum. Conversely, markers of angiogenesis (such as vascular endothelial growth factor-A [VEGF-A], heparin-binding epidermal growth factor, and hepatocyte growth factor) were reduced suggesting a blunting of the angiogenic response. Several of these changes were confirmed in the PMS CNS transcriptome. Lower levels of VEGF-A were associated with disability worsening on the timed-25 foot-walk test at 24 (p = 0.02) and 48 (p = 0.02) weeks and predicted disability worsening (hazard ratio 0.31, 95% CI 0.14-0.69, p = 0.034). Conversely, higher leptin levels trended to predict cognitive worsening on the symbol digit modalities test.
Discussion: Hypoxia-angiogenesis signals are dysregulated in PMS. Increased hypoxia and an insufficient angiogenic adaptive response may play a role in PMS pathophysiology and be a relevant pathway, both in understanding disease mechanisms and as a possible therapeutic target.
期刊介绍:
Neurology Neuroimmunology & Neuroinflammation is an official journal of the American Academy of Neurology. Neurology: Neuroimmunology & Neuroinflammation will be the premier peer-reviewed journal in neuroimmunology and neuroinflammation. This journal publishes rigorously peer-reviewed open-access reports of original research and in-depth reviews of topics in neuroimmunology & neuroinflammation, affecting the full range of neurologic diseases including (but not limited to) Alzheimer's disease, Parkinson's disease, ALS, tauopathy, and stroke; multiple sclerosis and NMO; inflammatory peripheral nerve and muscle disease, Guillain-Barré and myasthenia gravis; nervous system infection; paraneoplastic syndromes, noninfectious encephalitides and other antibody-mediated disorders; and psychiatric and neurodevelopmental disorders. Clinical trials, instructive case reports, and small case series will also be featured.